https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42463 p < 0.002) and smallest with metronidazole (22.7%, p = 0.18). Overall, 8.9% (95% confidence interval: 3.9-13.9) of patients had AEs severe enough to discontinue antibiotic therapy. In PSC patients, antibiotic treatment results in a significant improvement in markers of cholestasis and MRS. Antibiotics, particularly vancomycin, may have a positive effect on PSC either via direct effects on the microbiome or via host-mediated mechanisms.]]> Wed 24 Aug 2022 11:23:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32663 Wed 10 Nov 2021 15:04:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35004 Wed 02 Mar 2022 14:28:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34050 Thu 28 Oct 2021 13:03:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13376 Sat 24 Mar 2018 10:37:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13396 Sat 24 Mar 2018 10:35:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11215 Sat 24 Mar 2018 08:11:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18014 Sat 24 Mar 2018 07:56:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17933 Sat 24 Mar 2018 07:56:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5366 Sat 24 Mar 2018 07:43:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25147 Sat 24 Mar 2018 07:17:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24045 Sat 24 Mar 2018 07:09:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28017 Staphylococcus aureus (MRSA). Vancomycin remains an acceptable treatment option, with moves toward individualized dosing to a pharmacokinetic/pharmacodynamic (PK/PD) target. Numerous practicalities, however, would need to be resolved before implementation. Lipoglycopeptides as a class show excellent in vitro potency. Their long half-lives and complex PKs may preclude these agents being used in critically ill patients. Anti-MRSA cephalosporins provide great promise in the treatment of MRSA. These agents, despite broad-spectrum activity, should be reserved for patients with MRSA infections as it is likely that usage will be associated with increased rates of resistance. Daptomycin is currently the only antibiotic to have shown noninferiority to vancomycin in the treatment of MRSA bacteremia. The results of an open-labeled trial to address the superiority of daptomycin compared with vancomycin in reduced vancomycin susceptibility infections are eagerly anticipated. No drug to date has shown superiority to vancomycin in the treatment of MRSA infections with the possible exception of linezolid in hospital-acquired pneumonia (HAP), making linezolid an important option in the treatment of MRSA-proven HAP. Whether these strengths and features are agent or class specific are unclear but will likely be answered with the marketing of tedizolid. There are insufficient data to recommend either quinupristin/dalfopristin or tigecycline, as first line in the treatment of severe MRSA infections. These agents however remain options in patients with no other alternatives.]]> Fri 30 Jun 2017 16:44:10 AEST ]]>